Pipeline

TZ101 has been granted Orphan Drug Designation by the FDA in all our sought indications.

Fucosylation Enhances the Efficacy of Adoptively Transferred Antigen-specific-2019
Targazyme Presents TZ-102 Cancer Immunotherapy Preclinical Results at the World Orphan Drug Congress
Targazyme, Inc. Receives FDA Clearance For a Phase 2 Study of Pediatric Cancer Patients Undergoing Stem Cell Transplantation For Treatment of Hematologic Malignancies
Targazyme Inc. Receives Additional U.S Patent Award Designed to Improve Cell Therapy Clinical Efficacy Outcomes
Targazyme, Inc. Receives FDA Clearance For a Phase 2 Haplo-Identical Transplant Study of Patients Undergoing Bone Marrow Transplantation For Treatment of Hematologic Malignancies

2100 Palomar Airport Road
Suite 214-19
Carlsbad, CA 92011
Phone: 760.448.1168
Email: info@targazyme.com